SAN FRANCISCO, CA – GigaGen has won two Phase I grants from the National Cancer Institute’s highly competitive SBIR program. These Phase I grants support improvements in GigaGen’s technology for high-throughput genetic analysis of primary B cells. One project involves improvements to GigaGen’s antibody protein expression technology. The second project involves improvements to GigaGen’s microfluidic chip technology, which will improve throughput tenfold over the current design. CEO Dr. Johnson is the Principal Investigator for both grants.